Publications

• HogenEsch H, Orr MT, Fox CB (2023) Vaccine adjuvants: Mechanisms of action. In: Vaccine Development: From Concept to Clinic. Prasad KA, Ed. Royal Soc Chem, Cambridge, UK
• AbdelKhalek A, Ostafe R, Olave C, HogenEsch H, Turner JW Jr (2022) Effect of different adjuvant formulations on the antibody response of horses to porcine zona pellucida proteins. Vet Immunol Immunopathol 253:110507
• Hernandez-Franco JF, Xie S, Thimmapuram J, Ragland D, HogenEsch H (2022) Mechanism of activation of porcine dendritic cells by an α-D-glucan nanoparticle adjuvant and a nanoparticle/poly(I:C) combination adjuvant. Front Immunol 13: 990900
• Franco J, Rajwa B, Gomes P, HogenEsch H (2021) Local and systemic changes in lipid profile as potential biomarkers for canine atopic dermatitis. Metabolites, 11:670
• Hernandez-Franco J, Mosley YC, Franco J, Ragland D, Yao Y, HogenEsch H (2021) Effective and safe stimulation of humoral and cell-mediated immunity by intradermal immunization with a cyclic dinucleotide/nanoparticle combination adjuvant. J Immunol, 206: 700-711.
• Sundberg JP, Pratt CH, Godwin L, Silva KA, Kennedy VE, Potter CS, Dunham A, Sundberg BA, HogenEsch H (2020) Keratinocyte-specific deletion of SHARPIN induces atopic dermatitis-like inflammation in mice. PLoS One, 15:e0235295.
• Franco J, Rajwa B, Ferreira C, Sundberg JP, HogenEsch H (2020) Influence of sex and disease stage on epidermal lipid profiles in SHARPIN-deficient mice. Metabolites, 10:299.
• Lu F, Mosley YC, Brown D, Carmichael B, HogenEsch H (2019) Formulation of aluminum hydroxide adjuvant with TLR agonists poly(I:C) and CpG enhances the magnitude and avidity of the humoral immune response. Vaccine, 37:1945-1953.
• HogenEsch H, O'Hagan DT, Fox CB (2018) Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. Npj Vaccines, 3:51.